B · Normal
[Changchun High-tech: Subsidiary GenSci155 injection clinical trial application accepted] On October 20, Changchun High-tech (000661.SZ) announced that the company's controlled subsidiary Jinsai Pharmaceutical received the "Acceptance Notice" approved and issued by the State Food and Drug Administration, and the application for clinical trial registration of GenSci155 injection, a domestically produced drug, was accepted. The drug is a self-developed long-acting fatty acid-conjugated recombinant human insulin-like growth factor-1 analogue. It is intended to be used for the treatment of cerebral hemorrhage and is registered as a Class 1 therapeutic biological product.
A-share announcement express 🕐 2026-10-20 18:09
#clinical trial #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Yushu Technology: The humanoid robot industry is still in the early stages of c 10-20 19:04 [China Mobile: Net profit in the first three quarters fell 7.9% year-on-year] On 10-20 18:55 [Zhang Jianping, the third largest shareholder of Yunnan Germanium Industry, inc 10-20 18:52 [Yunnan Germanium Industry: Net profit in the first three quarters increased by 10-20 18:51 [Tianqi Lithium: Net profit is expected to increase by 2735%-3235% year-on-year 10-20 18:49 [OmniVision Group: Obtained a letter of commitment for a special repurchase loan 10-20 18:42

Comments

0/500
Captcha (click to refresh)
No comments yet